GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
News Oct 23, 2007
GeneGo, Inc. has announced that they have licensed their MetaCore Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5, includes GeneGo disease enrichment and functional ontology.
MetaCore has an in depth knowledge base for human diseases and the ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite's data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore a robust OMICs repository platform of choice. MetaCore is used in both research and clinical groups in drug development.
"We are pleased that AVEO chose the MetaCore suite of products to enhance its analytical capabilities," says Julie Bryant, Vice President of GeneGo. "AVEO's vision and focus in cancer drug research and development is inspiring and we believe our MetaCore suite of data mining tools will be an asset to their efforts."
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE